ArticleAAPS PharmSciTech2026
Transdermal Transport of a Geometric Self-Oscillating Copper Nanosystem for Topical Treatment of Psoriasis.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neogeometric copper nanoparticles (CuNPs) in drug delivery can be exploited for its cytotoxic effects and enhanced cellular uptake in dermatological conditions. The nanosystem, designed herein, is embedded in a Self-Oscillating Polymeric Network (SOPN) to stimulate the permeation of cubic CuNPs across the stratum corneum of induced psoriasiform-plaques in a BALB/c mouse model. Polymerization and cross-linking of the SOPN from NIPAM (N-isopropylacrylamide) and a metal salt exerted thermal and molecular differences of the resulting poly-NIPAM whilst maintaining inherent NIPAM thermo-responsive properties to control CuNP-permeation in an inflammatory environment. From an experimental design consisting of 15 formulations, it was found that thermo-responsive changes between 27-35˚C in the SOPN promoted the oscillatory behavior required for skin permeation of CuNPs where an oscillatory duration of 40 min was obtained. Viability analysis of the SOPN established biocompatible concentrations of the system for use in the in vivo model at reduced CuNP concentrations to control cytotoxicity (64.26-72.58%). The CuNP-loaded SOPN gel (60ug/mL) effectively promoted psoriatic-plaque resolution and hair growth, after 7 and 14 days of treatment, compared to the comparative (0.5% hydrocortisone cream). The geometric nanosystem embedded in an aqueous cream vehicle and the SOPN gel exhibited promising results in the reduction of in vivo psoriasiform-plaques compared to the gold standard.
Indexed as
Identifiers
42811245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.